H. David Humes

Feb 23, 2024 | onlinelibrary.wiley.com | Bertram Pitt |H. David Humes

Introduction Despite current therapy of patients hospitalized with acute (AHF) or worsening (WHF) heart failure, both heart failure with a reduced ejection fraction (HFrEF) and a preserved ejection fraction (HFpEF), there remains a relatively high incidence of cardiovascular (CV) mortality and hospitalizations for HF (HHF) at 30 and 90 days post-admission and/or discharge.1 The administration of sodium–glucose cotransporter inhibitors prior to and or shortly after discharge for AHF or WHF is...